Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for alprazolam
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alprazolam or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on alprazolam and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
terminated. (Please see Detailed Description for termination reason.) Sponsor: Pfizer Information provided by: Pfizer 2008 6. Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XRÂ® Tablets 3 mg Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles" Search for studies: Study Record Detail Fed Study of Alprazolam Extended-Release Tablets 3 (...) mg to Xanax XR® Tablets 3 mg This study has been completed. Sponsor: Mylan Pharmaceuticals Information provided (...) by: Mylan Pharmaceuticals ClinicalTrials.gov Identifier: NCT00650299 First received: March 30, 2008 Last updated: March 31, 2008 Last verified: March 2008 Full Text View Purpose The objective of this study was to investigate the bioequivalence of Mylan's alprazolam Extended-release 3 mg tablets to Pharmacia & Upjohn's Xanax XR® 3 mg tablets following a single, oral 3 mg (1 x 3 mg
Treating depression and anxiety with the benzodiazepine alprazolam: new Cochrane review recommends caution Treating depression and anxiety with the benzodiazepine alprazolam: new Cochrane review recommends caution Search National Elf Service Search National Elf Service » » » » Treating depression and anxiety with the benzodiazepine alprazolam: new Cochrane review recommends caution Jul 30 2012 Posted by Antidepressants and psychotherapies are the mainstay for treating depression, but another (...) option is the benzodiazepine drug alprazolam, which is recommended for treating depression when anxiety is also involved. Some doctors prescribe a short course of benzodiazepines to help depressed and anxious patients, but this is not supported by NICE guidance. High-potency tranquillisers like alprazolam are thought to have side-effects including dependence, rebound anxiety, memory impairment, accident-proneness and discontinuation syndrome. A new systematic review from the Cochrane Depression
A Xanax prescription that should have been rejected A Xanax prescription that should have been rejected A Xanax prescription that should have been rejected | | February 27, 2019 3K Shares In hindsight, I should have never accepted a Xanax prescription from my doctor. — rapidly developing and physical dependence on the drug and a prolonged illness. Three-and-a-half years later, I am still slowly tapering off Valium (having transitioned to a longer-acting benzodiazepine to aid in tapering (...) medication only as prescribed. can be intolerable and disabling in spite of a very slow taper over the course of years. The worst cases may become bedridden (or suffer severe symptoms such as ), unable to do basic self-care tasks most people take for granted such as showering or cooking. , but currently there is no research to predict which patients will have problems. Even commonly prescribed or “ ” of benzodiazepines can be problematic. I took the lowest dose of Xanax possible (even lower than my
Alprazolam-induced dose-dependent anorgasmia: case analysis Sexual dysfunctions are associated with multiple medical and psychiatric disorders, as well as pharmacotherapies used to treat these disorders. Although sexual dysfunctions negatively affect both quality of life and treatment adherence, patients infrequently volunteer these symptoms and clinicians do not pose directed questions to determine their presence or severity. This issue is especially important in psychiatric patients, for whom (...) most common psychotropics may cause sexual dysfunctions (antidepressants, antipsychotics, anxiolytics and mood-stabilising agents). There is limited literature addressing benzodiazepines, and alprazolam in particular.To report dose-dependent alprazolam anorgasmia.Case analysis with PubMed literature review.A 30-year-old male psychiatric patient presented with new-onset anorgasmia in the context of asymptomatic generalised anxiety disorder, social anxiety, panic disorder with agoraphobia, obsessive
Intervention/treatment Active Comparator: CBD (500 mg) CBD (500 mg) capsule by mouth one time during the 18 day treatment period Drug: THC THC capsule Drug: Alprazolam Alpraxolam capsule Other Name: Xanax Drug: Placebo oral capsule Sugar pill capsule Other Name: Placebo Active Comparator: CBD (1000 mg) CBD (1000 mg) capsule by mouth one time during the 18 day treatment period Drug: THC THC capsule Drug: Alprazolam Alpraxolam capsule Other Name: Xanax Drug: Placebo oral capsule Sugar pill capsule Other Name (...) : Placebo Active Comparator: THC (2.5 mg) THC 2.5 mg capsule by mouth one time during the 18 day treatment period Drug: Alprazolam Alpraxolam capsule Other Name: Xanax Drug: Placebo oral capsule Sugar pill capsule Other Name: Placebo Drug: CBD CBD capsule Active Comparator: THC (30 mg) THC 30 mg capsule by mouth one time during the 18 day treatment period Drug: Alprazolam Alpraxolam capsule Other Name: Xanax Drug: Placebo oral capsule Sugar pill capsule Other Name: Placebo Drug: CBD CBD capsule Active
The Effect of Chronic Alprazolam Intake on Memory, Attention, and Psychomotor Performance in Healthy Human Male Volunteers. Alprazolam is used as an anxiolytic drug for generalized anxiety disorder and it has been reported to produce sedation and anterograde amnesia. In the current study, we randomly divided 26 healthy male volunteers into two groups: one group taking alprazolam 0.5 mg and the other taking placebo daily for two weeks. We utilized the Cambridge Neuropsychological Test Automated (...) Battery (CANTAB) software to assess the chronic effect of alprazolam. We selected Paired Associates Learning (PAL) and Delayed Matching to Sample (DMS) tests for memory, Rapid Visual Information Processing (RVP) for attention, and Choice Reaction Time (CRT) for psychomotor performance twice: before starting the treatment and after the completion of the treatment. We found statistically significant impairment of visual memory in one parameter of PAL and three parameters of DMS in alprazolam group
Alprazolam as an adjunct to propranolol in anxious outpatients with stable angina pectoris. A double-blind crossover comparison is reported of the effects of alprazolam and placebo on anxiety and angina in 27 ambulatory outpatients with angina pectoris stabilized on propranolol. Alprazolam was shown to be a safe treatment when combined with propranolol in these patients. Patients receiving alprazolam with propranolol reported more improvement on their targeted symptoms than did patients (...) receiving placebo with propranolol. The side effect most often reported was moderate drowsiness or sedation; no unusual side effects emerged. There was no evidence that alprazolam compromised the patients' response to propranolol.
Alprazolam for essential tremor. Essential tremor (ET) is one of the most common movement disorders. Treatment is based primarily on pharmacological agents. On this basis, although primidone and propranolol are well-established treatments in clinical practice, they could be ineffective in 25% to 55% of patients and can produce serious adverse events (AEs) in a large percentage of individuals. For these reasons, evaluating treatment alternatives for ET may be a worthwhile pursuit. Alprazolam has (...) been suggested as a potentially useful agent for treatment of individuals with ET, but its efficacy and safety are uncertain.PrimaryTo assess the efficacy and safety of alprazolam in the treatment of individuals with ET. SecondaryTo examine effects of alprazolam treatment on the quality of life of people with ET.We carried out a systematic search without language restrictions to identify all relevant trials. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January
Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Infrahuman and human studies suggest that a determinant of the abuse potential of a drug is rate of onset of subjective effects.This study sought to determine if the rate of onset of subjective effects and abuse potential of alprazolam would be increased when administered via inhalation vs. the oral route.Placebo, inhaled alprazolam (0.5, 1, and 2 mg), and oral alprazolam (1, 2 (...) , and 4 mg) were administered under double-blind, double-dummy conditions using a crossover design in 14 healthy participants with histories of drug abuse. Participant and observer ratings and behavioral and cognitive performance measures were assessed repeatedly during 9-h sessions.Both routes of administration produced orderly dose and time-related effects, with higher doses producing greater and longer-lasting effects. Onset of subjective effects following inhaled alprazolam was very rapid (e.g., 2
Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders. Panic disorder affects 2-5% of the general population. In Argentina, one million people would be affected with a 91% rate of psychiatric comorbidity. AIM; To compare efficacy parameters between sublingual (ALP-SL) and conventional (ALP-CT) tablets of alprazolam in the treatment of acute phase of panic disorder with and without agoraphobia.A comparative, multicenter (6 sites), double blind (...) and anticipatory anxiety. RESULTS. Both treatments resulted in statistically significant clinical improvement in all measures. ASEX presented no changes during the study. The average dose of alprazolam for 12 weeks was 1.36 ± 0.70 mg/day (1.39 ± 0.77 ALP-CT and 1.33 ± 0.64 ALP-SL). With ALP-SL, panic attacks were shorter (p < 0.05) with shorter extension (p=0.16) and intensity of anticipatory anxiety (p=0.14). The treatment was well tolerated, there being no differences between both groups.Alprazolam has been
A Case of Unintentional Opioid (U-47700) Overdose in a Young Adult After Counterfeit Xanax Use. We report the case of a young adult who became unresponsive after insufflating what he believed to be "crushed Xanax." Naloxone was administered, reversing his altered mental status and respiratory depression. Clinicians suspected opioid toxicity; however, the patient adamantly denied opioid use. Because of unclear etiology of his symptoms, blood and urine specimens were obtained. A urine specimen (...) time-of-flight mass spectrometry and liquid chromatography tandem mass spectrometry confirmed the presence of U-47700 (a high-potency clandestine opioid) and its metabolites in the urine and blood. These findings implicate U-47700 as the agent responsible for the patient's signs of opioid toxicity. In this case, a young adult intending to use alprazolam encountered U-47700 with life-threatening effect. Clinicians must remain vigilant for symptoms consistent with opioid overdose, especially
Pharmacokinetic Study Evaluating StaccatoÂ® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03516305 Recruitment Status : Completed First Posted : May 4, 2018 Last Update Posted : December 18, 2018 Sponsor
Paradoxical Reaction to Alprazolam in an Elderly Woman with a History of Anxiety, Mood Disorders, and Hypothyroidism With less than 1% of patients who use benzodiazepines being affected, paradoxical responses to benzodiazepines are rare. In this case report, we outline the course of an 80-year-old female who developed a paradoxical response to benzodiazepines. Significant medical and psychiatric history includes anxiety, mood disorder, hypothyroidism, bilateral mastectomy, goiter removal (...) , and triple bypass. The patient presented with mental status changes, anxiety, motor restlessness, and paranoia. Over time, a temporal relationship between the severity of the patient's motor agitation and intake of alprazolam was observed. As doses of alprazolam were decreased, her motor agitation became less severe. In addition to motor agitation, the patient also demonstrated increased aggressiveness, a subjective feeling of restlessness, and increased talkativeness. As her dose of alprazolam decreased
Temporal profile of brain response to alprazolam in patients with generalized anxiety disorder. This study investigated the temporal pattern of brain response to emotional stimuli during 28 days of alprazolam treatment among patients with generalized anxiety disorder (GAD) randomized 2:1 to drug or placebo in a double-blind design. Functional magnetic resonance imaging scans obtained during an emotion face matching task (EFMT) and an affective stimulus expectancy task (STIMEX) were performed (...) at baseline, one hour after initial drug administration and 28 days later. Alprazolam significantly reduced scores on the Hamilton Anxiety Scale and the Penn State Worry Questionnaire after one week and 28 days of treatment. Brain activation in the amygdala during the EFMT and in the insula during the STIMEX was reduced one hour after alprazolam administration but returned to baseline levels at Day 28. Exploratory analyses revealed significant treatment differences in brain activity during the STIMEX
StaccatoÂ® Alprazolam and EEG Photoparoxysmal Response Staccato Alprazolam and Photoparoxysmal Response - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Staccato Alprazolam and Photoparoxysmal Response (...) , Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to determine whether people who usually have photosensitive epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato Alprazolam as compared to placebo. Condition or disease Intervention/treatment Phase Epilepsy Drug: Staccato® Alprazolam, 0.5 mg Drug: Staccato® Alprazolam, 1 mg Drug: Staccato® Alprazolam, 2 mg Drug: Staccato® Placebo (a) Drug: Staccato® Placebo (b) Phase 2
Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XRÂ® Tablets 3 mg Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00650299 Recruitment Status : Completed First Posted : April 1, 2008 Last Update Posted : April 1, 2008 Sponsor: Mylan Pharmaceuticals Information provided by: Mylan
medications are given in a counterbalanced design. Drug: Zolpidem Other Name: Ambien Drug: Alprazolam Other Name: Xanax Drug: Caffeine Other Name: No Doz Other: Placebo Outcome Measures Go to Primary Outcome Measures : Change in blood oxygen level-dependent (BOLD) signal as measured with fMRI [ Time Frame: 45 min after drug administration ] Secondary Outcome Measures : Change in subjective drug effects as measured by self-report questionnaires [ Time Frame: Over the course of 6 hours ] Eligibility (...) Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Imaging
Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. The authors present interim results of a prospective, random assignment, double-blind, placebo-controlled trial conducted to determine whether clonazepam is as effective as alprazolam in reducing the frequency of panic attacks and whether both agents are superior to placebo. Analysis on 44 of 60 randomized subjects showed no statistically (...) significant differences between the clonazepam and alprazolam groups on the following clinically meaningful outcome measures: total number of panic attacks and percent of time subjects experienced anticipatory anxiety, extent of phobic avoidance, and fear. Statistically significant differences did exist among the drug and placebo groups on these measures. The authors conclude that this interim analysis of the data supports the inclusion of clonazepam in the treatment of panic disorder.